Nathan B. Fountain - 09 Jun 2026 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Reporting relationship: Director
Issuer ticker: ABOS
Reported as of: 09 Jun 2026
Net transaction value: -$14,273
SEC form: 4
Accepted by SEC: 10 Jun 2026, 16:51:13 UTC
Prior SEC filing: 05 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Derek Meisner, Attorney-in-Fact

Key filing fact

Nathan B. Fountain filed Form 4 for Acumen Pharmaceuticals, Inc. (ABOS) on 10 Jun 2026.

Key facts

This page summarizes Nathan B. Fountain's Form 4 filing for Acumen Pharmaceuticals, Inc. (ABOS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 10 Jun 2026, 16:51.

Change

Previous filing in this sequence was filed on 05 Jun 2026.
Current net transaction value: -$14,273.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001869596 Primary reporting owner

Fountain Nathan B

Relationship: Director
Address: C/O ACUMEN PHARMACEUTICALS, INC., 1210-1220 WASHINGTON STREET, SUITE 210, NEWTON
Signature: /s/ Derek Meisner, Attorney-in-Fact
Signature date: 10 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABOS transaction

Common Stock

Sale

Transaction value: $14,273
Shares: -6,400
Change %: -12%
Price: $2.23
Shares after: 48,150
Date: 09 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.2300 to $2.2311. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.